Tallinn harbour’s Q3 2026 cargo volumes slipped while passenger traffic rose modestly, highlighting divergent freight and travel trends
Executive summary: AS Tallinna Sadam handled 3.3 million tonnes of cargo and 2.8 million passengers in Q3 2026; cargo fell 3.3% (‑110 000 t) while passengers rose 2.1% (+57 000) YoY. The divergent trends signal weakening freight demand but a modest travel recovery, affecting port revenues and indicating broader Baltic‑Sea trade and tourism shifts.
Who is involved: AS Tallinna Sadam (port operator), its customers (freight shippers and ferry operators), and Estonian transport authorities.
Likely next (inference): Port management will monitor monthly cargo and passenger figures, adjust tariff policies if freight weakness persists, and prepare for winter season travel patterns.
In the third quarter of 2026, AS Tallinna Sadam handled 3.3 million tonnes of cargo and 2.8 million passengers. Cargo volume fell 3.3% year‑on‑year, equivalent to 110 000 tonnes less, while passenger numbers grew 2.1% (+57 000). The shift suggests weakening demand for freight through the port, offset by a modest recovery in travel, possibly reflecting broader Baltic‑Sea trade patterns and seasonal tourism flows.
What's next — scenarios
Inference: scenarios and probabilities are Beyond's assessment, not reported fact.
Base case: modest cargo decline, steady passenger growth (40%)
Port revenues stable with modest passenger uplift offsetting slight cargo decline.
- Quarterly cargo tonnage >‑2% YoY decline
- Passenger growth >+1.5% YoY
- Brent oil price stays $95‑$110
Upside: new trade routes and tourism boost volumes (30%)
Higher stevedore and quayage fees boost port EBITDA by ~8%.
- Signing of new freight‑forwarding agreements with Nordic shippers
- Tourist arrivals to Estonia exceed 2025 levels by 10%
- Brent oil falls below $90
Downside: global slowdown and high bunker costs weigh on volumes (30%)
Port operating margin contracts ~5% as fixed costs outweigh reduced throughput.
- Brent oil exceeds $120 for two consecutive months
- EU manufacturing PMI falls below 45
- Passenger surveys show <‑1% YoY change
What to watch
- Quarterly cargo tonnage report from AS Tallinna Sadam (expected early January 2027)
- Monthly passenger statistics from Tallink Grupp (released end of each month)
- Brent crude oil price average (monitored weekly; threshold $110)
- Baltic Dry Index (weekly) as proxy for global freight demand
- Estonian tourism board monthly visitor numbers (released monthly)
Timeline
- — AS Tallinna Sadam operational volumes for 2026 Q3 and 9 months (GlobeNewswire)
- — AS-i Tallink Grupp 2026. aasta septembri ja III kvartali statistika (GlobeNewswire)
Analysis — what this means
Likely next events
- AS Tallinna Sadam to release Q4 2026 cargo and passenger figures on 10 January 2027
- Tallink Grupp to publish October 2026 passenger traffic on 5 November 2026
- Brent oil OPEC meeting scheduled for 30 November 2026 to decide output policy
- Baltic Dry Index to be published weekly; watch for sustained >1500 points signalling freight rebound
Sectors affected
- Port and stevedoring services
- Ferry passenger transport
- Oil and bunker fuel suppliers
- Logistics and freight forwarding
Historical parallels
- 2020‑2021 COVID‑19 pandemic caused Baltic‑Sea passenger traffic to drop >40% and cargo volumes to fall ~10%
- 2015‑2016 oil surplus drove Brent prices below $30/barrel, cutting bunker costs and boosting port cargo
- 2022 Russia‑Ukraine war disrupted Baltic‑Sea freight flows, cutting cargo through Estonian ports by ~15%
Key entities
Sources
- AS Tallinna Sadam operational volumes for 2026 Q3 and 9 months — GlobeNewswire
- AS-i Tallink Grupp 2026. aasta septembri ja III kvartali statistika — GlobeNewswire
Related cases
- FDA’s approval of Roche’s Tecentriq for adjuvant colon cancer expands immunotherapy options and promises a new revenue stream for the drug
- TextMagic posts 12% YoY revenue growth in Q3 2026, reaching €3.6 million
- Akeso initiates first patient enrollment in global Phase III trial comparing its PD-1/LAG-3 bispecific cadonilimab to nivolumab for first-line gastric cancer
- XTEND advances to Phase III of U.S. SOCOM modular drone program, reinforcing its position in the drone dominance market
- Akeso secures major clinical spotlight at ESMO 2026 with breakthrough Phase III biliary tract cancer survival data
- Antengene initiates pivotal Phase III CLINCH-3 trial of ATG-022, advancing its oncology pipeline